Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia

Leuk Lymphoma. 2017 May;58(5):1254-1257. doi: 10.1080/10428194.2016.1235273. Epub 2016 Oct 5.

Authors

Sakiko Yoshida¹, Emily Tuscano², Connie Duong¹, Jong Chung¹, Yueju Li³, Laurel Beckett³, Joseph M Tuscano², Noriko Satake¹

Affiliations

¹ a Department of Pediatrics , University of California , Davis , CA , USA.
² b Department of Internal Medicine , University of California , Davis , CA , USA.
³ c Department of Public Health Sciences , University of California , Davis , CA , USA.

No abstract available

Publication types

Letter

MeSH terms

Animals
Antibodies, Monoclonal / chemistry
Antibodies, Monoclonal / pharmacology*
Antineoplastic Agents, Immunological / pharmacology*
Cell Line, Tumor
Cell Survival / drug effects
Child, Preschool
Disease Models, Animal
Drug Evaluation, Preclinical
Humans
Immunoconjugates / chemistry
Immunoconjugates / pharmacology*
Male
Mice
Molecular Targeted Therapy
Oligopeptides* / chemistry
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
Sialic Acid Binding Ig-like Lectin 2 / antagonists & inhibitors*
Xenograft Model Antitumor Assays

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoconjugates
Oligopeptides
Sialic Acid Binding Ig-like Lectin 2
monomethyl auristatin E

Grants and funding